<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to older males with low testosterone</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to older males with low testosterone</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Approach to older males with low testosterone</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alvin M Matsumoto, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth E Schmader, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H492917774"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>As males age, their serum concentrations of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> decrease. This decline is gradual and of a modest degree, but because many of the changes of aging are similar to those of hypogonadism due to known disease, the decline in testosterone has been postulated to be a cause of these changes of aging. Recent studies show that raising the testosterone levels of older males with low testosterone has some benefits, but no study yet has enrolled enough males and treated and observed them for long enough to determine the risk of this treatment.</p><p>The decline in testicular function with aging, its possible consequences, and the results of increasing <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> levels in older males are reviewed here. Testosterone treatment of male hypogonadism due to known disease is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism"</a>.)</p><p class="headingAnchor" id="H3886115599"><span class="h1">AGE-RELATED ENDOCRINE CHANGES</span><span class="headingEndMark"> — </span>Both cross-sectional and longitudinal studies demonstrate a decline in serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> concentration, an increase in sex hormone-binding globulin concentration (SHBG), and a decrease in free testosterone with age.</p><p class="headingAnchor" id="H3929051218"><span class="h2">Serum total testosterone</span><span class="headingEndMark"> — </span>Several cross-sectional studies show a decline of serum total <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> concentration with increasing age [<a href="#rid1">1,2</a>]. In one, the European Male Aging Study (EMAS), of 3220 males ages 40 to 79 years, the serum total testosterone concentration fell 0.4 percent per year [<a href="#rid1">1</a>]. In a second study, a gradual decline in testosterone concentration was seen after age 35 years, with a more marked decline after age 80 years [<a href="#rid2">2</a>].</p><p>In a study using serum samples from four population-based studies (EMAS, Framingham Heart Study, Osteoporotic Fractures in Men [MrOS], Male Sibling Study of Osteoporosis) of males from ages 19 to 79 that were assayed and standardized against gold-standard measurements performed at the Centers for Disease Control and Prevention (CDC), age-specific harmonized reference ranges were generated. This study demonstrated that the lowest 2.5<sup>th</sup> percentile values decreased considerably with age, but the 50<sup>th</sup> percentile value decreased much less and the 97.5<sup>th</sup> values not at all [<a href="#rid3">3</a>]. For example, the 2.5<sup>th</sup> percentile model estimate for all males and nonobese males 19 to 39 years was 229 ng/dL and 264 ng/dL, respectively, and that for all males 70 to 79 years was 119 ng/dL, whereas the values for the 50<sup>th</sup> percentile were 507 and 446 ng/dL and for the 97.5<sup>th</sup> percentile were 902 and 902 ng/dL, respectively.</p><p>Longitudinal studies also show a decrease in <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> with increasing age, and in three of them, the decrease was greater than that in cross-sectional studies [<a href="#rid4">4-6</a>]. In 890 males participating in the Baltimore Longitudinal Study of Aging, serum testosterone decreased at a fairly constant rate, independent of other clinical variables [<a href="#rid6">6</a>]. In the Massachusetts Male Aging Study, longitudinal assessment also showed a decrease in total testosterone with increasing age but a greater decrease in free testosterone [<a href="#rid4">4,5</a>].</p><p>Another feature of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> with increasing age is a loss of circadian rhythmicity. Whereas young males exhibit a prominent increase in the morning, peaking at approximately 8 AM, older males show a very dampened increase  (<a class="graphic graphic_figure graphicRef79127" href="/z/d/graphic/79127.html" rel="external">figure 1</a>) [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H120039047"><span class="h2">Serum sex hormone-binding globulin</span><span class="headingEndMark"> — </span>SHBG concentrations increase gradually as a function of age, as shown in the EMAS [<a href="#rid1">1</a>]. The clinical implication, because SHBG binds <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> with high affinity, is that with increasing age, less of the total testosterone is free (ie, biologically active). SHBG, however, is lower at all ages in obese males than in nonobese males [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H2669437614"><span class="h2">Serum free testosterone</span><span class="headingEndMark"> — </span>The serum free <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> concentration decreases with increasing age to a greater degree than the total testosterone; the values in 75 to 79-year-old males were approximately 30 percent less than those in 40 to 44-year-old males [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H4216363068"><span class="h2">Effects of obesity and comorbid conditions</span><span class="headingEndMark"> — </span>The total <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> levels in obese males are lower than those in males of normal weight of the same age, partly due to a lower level of SHBG in obesity, but partly due to hypogonadotropic hypogonadism, since their free testosterone levels are also lower those of nonobese males and their luteinizing hormone (LH) levels are not higher  (<a class="graphic graphic_figure graphicRef117098" href="/z/d/graphic/117098.html" rel="external">figure 2</a>) [<a href="#rid1">1</a>]. Total and free testosterone levels are lower in males who have one or more comorbid conditions than in males of the same age who have none and their LH levels are not higher, suggesting that they also have hypogonadotropic hypogonadism [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H974799785"><span class="h2">Change in gonadotropins</span><span class="headingEndMark"> — </span>As males age, serum gonadotropin concentrations increase, follicle-stimulating hormone (FSH) more than LH, but the rise is not so great as one would expect from the fall in <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a>, suggesting that the fall in testosterone with aging is due to both secondary and primary hypogonadism.</p><p>In the EMAS, the fall in <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> with age was associated with an increase in LH, suggesting a degree of primary hypogonadism [<a href="#rid1">1</a>], but the fall in testosterone with obesity alone (without aging) was not, suggesting that the effect of obesity was mediated by hypogonadotropic hypogonadism.</p><p class="headingAnchor" id="H3601741301"><span class="h2">Effects on spermatogenesis</span><span class="headingEndMark"> — </span>Sperm production does not appear to change dramatically with increasing age. Testicular size, which reflects primarily the volume occupied by the seminiferous tubules, was somewhat smaller (mean volume 20.6 mL) in 114 older males than in 42 young males (29.7 mL) [<a href="#rid8">8</a>]. Ejaculated sperm density in 20 fathers ages 24 to 37 years old was slightly lower than that in 22 grandfathers ages 60 to 88 years old, but percent motility was greater in the younger group, resulting in a similar total number of motile sperm in the two groups [<a href="#rid9">9</a>].</p><p>In 1174 males recruited for studies of erectile function, the oldest quartile, who were aged 56 to 80 years, had similar semen characteristics to the youngest quartile, aged 45 to 47.8 years [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H2505005012"><span class="h1">ARE THERE CONSEQUENCES OF AGE-RELATED FALL IN TESTOSTERONE?</span><span class="headingEndMark"> — </span>No clinical consequences of the decline in serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> with age are known with certainty, but several parallels between the effects of aging and those of hypogonadism due to pituitary or testicular disease suggest that the decline in serum testosterone might be a cause of several effects of aging. The parallels include a decline in libido and sexual activity, decreased muscle mass and strength, depressed mood, decreased bone mineral density (BMD), and anemia. (See  <a class="medical medical_review" href="/z/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism"</a>.)</p><p>Hypogonadism is actually uncommon in older males. In a report from the European Male Aging Study (EMAS), 2,966 males aged 40 to 79 were evaluated to determine if males with a low serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> concentration for no apparent reason other than age develop the typical signs and symptoms of male hypogonadism due to known pituitary or testicular disease [<a href="#rid11">11</a>]. The combination of low serum testosterone (&lt;317 ng/dL [11 nmol/L]) and three sexual symptoms, was seen in only 2.1 percent of males (n = 63). More severe hypogonadism (serum testosterone concentration &lt;230 ng/dL [8 nmol/L]) was seen in 27 of the 63 (0.9 percent) hypogonadal males. </p><p>The hypogonadal males tended to be older and more obese, and in proportion to their <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> deficiency they had significantly lower:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin</p><p class="bulletIndent1"><span class="glyph">●</span>Heel bone mineral density</p><p class="bulletIndent1"><span class="glyph">●</span>Muscle mass</p><p class="bulletIndent1"><span class="glyph">●</span>Poorer general health</p><p></p><p>Severe hypogonadism was also associated with insulin resistance and the metabolic syndrome. The associations were stronger when the serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> concentration was &lt;230 ng/dL (8 nmol/L) than when it was in the 230 to 317 ng/dL range (8 to 11 nmol/L). These data support the concept of a low testosterone syndrome in middle-aged and older males, but only in a small percentage.</p><p class="headingAnchor" id="H1278212451"><span class="h1">EVALUATION FOR POSSIBLE HYPOGONADISM</span></p><p class="headingAnchor" id="H1164132347"><span class="h2">Who should be tested?</span><span class="headingEndMark"> — </span>We do not routinely measure serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> in older males. However, older males who have symptoms (eg, decreased libido, depressive mood), physical findings (eg, decreased body hair), or laboratory findings (eg, anemia, low bone mineral density [BMD]) of low testosterone should be evaluated in the same way as younger symptomatic males. (See  <a class="medical medical_review" href="/z/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism"</a>.)</p><p class="headingAnchor" id="H3340960707"><span class="h2">Biochemical testing</span></p><p class="bulletIndent1"><span class="glyph">●</span>The initial test should be a serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> measurement early in the morning, fasting. If the result is low, the test should be repeated at least once, preferably twice.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> should be measured in a laboratory that performs the assay by liquid chromatography and tandem mass spectroscopy and that participates in the Center for Disease Control and Prevention (CDC)'s accuracy-based <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Flabstandards%2Fhs.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLFIScUk1Y%2FA6K3ujbEhk90ntqdq00Q4z%2BhL0arOPd9DbrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=7457" target="_blank">testosterone Hormone Standardization (HoSt) program</a> or uses an immunoassay that participates in the HoSt program. In a study using sera from four population studies and a harmonized testosterone assay, the lower limit (2.5<sup>th</sup> percentile) for nonobese males 19 to 39 years was 264 ng/dL [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> results are consistently low, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) should be measured to determine if the hypogonadism is primary or secondary. (See  <a class="medical medical_review" href="/z/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism", section on 'LH and FSH'</a>.)</p><p></p><p class="bulletIndent1">If secondary, other pituitary hormonal deficiencies should be evaluated. (See  <a class="medical medical_review" href="/z/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism", section on 'Pituitary function testing'</a>.)</p><p></p><p class="bulletIndent1">If the hypogonadism is secondary and of moderate severity (eg, &lt;200 ng/dL) and/or associated with other hormonal deficiencies, magnetic resonance imaging (MRI) of the sella area should be ordered.</p><p></p><p class="headingAnchor" id="H516808901"><span class="h1">TESTOSTERONE THERAPY</span></p><p class="headingAnchor" id="H3826753931"><span class="h2">Testosterone currently overprescribed for males without hypogonadism</span><span class="headingEndMark"> — </span>There has been a dramatic increase in inappropriate use of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy in healthy, middle-aged and older males [<a href="#rid12">12</a>]. This rise is likely due, at least in part, to direct-to-consumer advertising encouraging use of testosterone products for nonspecific symptoms, such as decreased energy and sexual interest. However, treatment is only appropriate for those with well documented hypogonadism as described in the following section.</p><p class="headingAnchor" id="H137689270"><span class="h2">Potential candidates for therapy</span><span class="headingEndMark"> — </span>Whether or not older males who have low <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> for no discernable reason other than age will benefit from testosterone treatment is controversial. In contrast, there is general agreement that older males who have unequivocally low testosterone due to known hypothalamic-pituitary or testicular disease should be treated with testosterone as younger males. In 2015, the US Food and Drug Administration (FDA) directed manufacturers of testosterone products to state in their labels that these products are approved only for males with low testosterone due to known causes [<a href="#rid13">13</a>].</p><p>However, other expert groups argue that there may be a role for <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy in selected patients. Our approach is similar to the Endocrine Society Clinical Practice Guidelines for testosterone therapy in adult males with testosterone deficiency, which were updated in 2018 [<a href="#rid14">14</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>We suggest offering <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> on an individualized basis to older males who have symptoms and conditions suggestive of testosterone deficiency and who have consistently and unequivocally low serum testosterone levels after explicit discussion of the potential risks and benefits.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, we suggest against routinely prescribing <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> to older males with low testosterone levels in the absence of symptoms and conditions of androgen deficiency (or symptoms without unequivocally low testosterone levels).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As with hypogonadism due to known disease, <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> treatment should not be initiated until further evaluation if the patient has a prostate nodule, a prostate-specific antigen (PSA) &gt;4 ng/mL or &gt;3 ng/mL in males at increased risk of prostate cancer (eg, African American males or those who have a first-degree relative with diagnosed prostate cancer), or a hematocrit &gt;48 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The same <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> preparations available for younger males can be used for older males. (See  <a class="medical medical_review" href="/z/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism"</a>.)</p><p></p><p class="headingAnchor" id="H3228634760"><span class="h2">Efficacy</span><span class="headingEndMark"> — </span>Data from five randomized, placebo-controlled trials including over 500 older males [<a href="#rid15">15-21</a>] during the 1990s showed some beneficial effects of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> treatment in older males, but the results were not consistent, possibly because of enrolling males who were not clearly hypogonadal, not increasing the serum testosterone to normal, insufficient duration of treatment, and/or not choosing clinically important outcomes. A committee of the Institute of Medicine (now the National Academy of Medicine) reviewed these and other trials and concluded that there was insufficient evidence to conclude that testosterone treatment of older males has any well-established benefit. The committee recommended that a coordinated set of randomized, placebo-controlled clinical trials should be performed to determine if testosterone does have any benefit [<a href="#rid22">22</a>]. The Testosterone Trials (TTrials) were designed to implement this recommendation.</p><p class="headingAnchor" id="H3880181295"><span class="h2">The Testosterone Trials</span></p><p class="headingAnchor" id="H3358752453"><span class="h3">Design</span><span class="headingEndMark"> — </span>The multicenter TTrials were a coordinated set of seven placebo-controlled clinical trials to test the one-year efficacy of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> on sexual function, physical function, vitality, cognitive function, anemia, bone density, and cardiovascular risk factors in older males with symptoms of hypogonadism and consistently low testosterone [<a href="#rid23">23</a>].</p><p>Males over age 65 years (n = 788) with low serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> (&lt;275 ng/dL [9.54 nmol/L] early in the morning on two occasions) and symptoms and objective evidence of sexual dysfunction, physical dysfunction, and/or reduced vitality were assigned to receive testosterone or placebo gel with balancing by minimization for one year and participated in one or more of three main trials (the sexual function [n = 470], physical function [n = 390], and vitality [n = 474] trials). They could also participate in any of the other trials for which they qualified.</p><p class="headingAnchor" id="H658503740"><span class="h3">Outcomes</span><span class="headingEndMark"> — </span>Over 51,000 males were screened to enroll the 790 males who met inclusion criteria (only 1.5 percent of those screened). The median pretreatment <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> concentration was 232 ng/dL. After one year of testosterone gel therapy, average serum testosterone concentrations increased into the mid-normal range (approximately 500 ng/dL) for males ages 19 to 40 years. The following results were reported:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sexual function</strong> – <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> therapy was associated with a moderate improvement in sexual function, including sexual activity  (<a class="graphic graphic_figure graphicRef117276" href="/z/d/graphic/117276.html" rel="external">figure 3</a>), sexual desire (libido), and, to a lesser extent, erectile function [<a href="#rid24">24</a>]. The effect on sexual activity and sexual desire was likely of clinical significance because the effect sizes were 0.45 and 0.44, respectively, and participants who were treated with testosterone were significantly more likely than those treated with placebo to respond on a Patient Global Assessment of Change question that their sexual desire was better during treatment than before. The magnitude of rise in serum testosterone and estradiol concentrations was associated with the magnitude of improvement in sexual desire and sexual activity, but not erectile function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical function</strong> – There was no significant difference between the testosterone- versus placebo-treated groups in walking distance on a six-minute walk test in the 390 males who were enrolled in the physical function trial, but <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> did improve walking distance when all 788 males were included [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitality</strong> – (as assessed by Functional Assessment of Chronic Illness Therapy-Fatigue Scale in the vitality trial) did not differ in testosterone- versus placebo-treated males enrolled in the vitality trial (but <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> improved vitality [energy] slightly when subjects from all three main trials were included) [<a href="#rid23">23</a>]. However, males receiving testosterone reported better mood and lower severity of depressive symptoms when compared with placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cognitive function</strong> – A subgroup of 493 males in the TTrials met criteria for age-associated memory impairment (AAMI), based on subjective memory complaints and objective memory performance lower than younger males [<a href="#rid25">25</a>]. After 6 and 12 months, there were no differences in changes from baseline in testosterone- and placebo-treated males in test scores for memory and other cognitive functions (delayed paragraph recall, visual memory, executive function, or spatial ability), but <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> improved executive function when all subjects from all three main trials were included.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anemia</strong> – Among the 788 males enrolled in all three trials, 126 were anemic (hemoglobin ≤12.7 g/dL) at baseline, 64 associated with a known cause, such as iron deficiency, and 62 with unexplained anemia [<a href="#rid26">26</a>]. After 12 months of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> treatment, more males with unexplained anemia in the testosterone group had increases in hemoglobin of 1 g/dL or more (54 versus 15 percent in the placebo group) and normal hemoglobin values (58 versus 22 percent in the placebo group)  (<a class="graphic graphic_figure graphicRef117099" href="/z/d/graphic/117099.html" rel="external">figure 4</a>). Similar results occurred in males who had anemias of known cause  (<a class="graphic graphic_figure graphicRef117183" href="/z/d/graphic/117183.html" rel="external">figure 5</a>). This effect of testosterone replacement is consistent with the known stimulatory effect of testosterone on erythropoiesis. Another trial also suggested benefit for anemia [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone density</strong> – A subgroup of 211 males underwent assessment of volumetric bone mineral density (vBMD) and bone strength by quantitative computed tomography (QCT) scanning at baseline and 12 months [<a href="#rid28">28</a>]. After 12 months, <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> significantly increased mean lumbar spine trabecular vBMD (7.5 versus 0.8 percent), as well as lumbar peripheral and hip trabecular and peripheral vBMD  (<a class="graphic graphic_figure graphicRef117100" href="/z/d/graphic/117100.html" rel="external">figure 6</a>), and mean estimated strength of spine trabecular bone (11 versus 2.4 percent), as well as lumbar peripheral and hip trabecular and peripheral bone  (<a class="graphic graphic_figure graphicRef117184" href="/z/d/graphic/117184.html" rel="external">figure 7</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse events</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Coronary artery plaque</strong> – In a substudy of 170 males, one year of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy was associated with a greater increase than placebo in noncalcified coronary artery plaque volume, as measured by coronary computed tomographic angiography (CCTA) [<a href="#rid29">29</a>]. There was also a significantly greater increase in total plaque volume in the testosterone group but no change in the coronary calcification score in either group. Of note, 50 percent of the study subjects had severe atherosclerosis at baseline on CCTA. Major limitations of the study were the use of CCTA (a surrogate outcome for atherosclerosis) and the small size and short duration of the trial. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Erythrocytosis</strong> – More males in the <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> group experienced erythrocytosis (hemoglobin ≥17.5 g/dL) (7 versus 0) [<a href="#rid23">23</a>]. The incidence of major adverse cardiovascular events and other adverse events was otherwise similar with testosterone and placebo.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prostate outcomes</strong> – In the same set of trials, <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy that increased serum testosterone concentrations from moderately low (approximately 230 ng/dL [7.97 nmol/L]) into the midnormal range (approximately 500 ng/dL [17.3 nmol/L]) increased serum PSA concentrations to a small degree [<a href="#rid30">30</a>]. Only 2.5 percent of males experienced an increase above baseline of ≥3.4 ng/mL, A confirmed PSA &gt;4.0 ng/mL occurred in 1.9 percent of males on testosterone and 0.3 percent on placebo. </p><p></p><p class="bulletIndent2">Four prostate cancers were diagnosed during the 12 months of treatment and the 6 months of follow-up; three in the <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> arm (two of which were high-grade prostate cancer) and one in the placebo arm.</p><p></p><p class="bulletIndent1">The TTrials, in short, demonstrated that <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> treatment of symptomatic older males with unequivocally low testosterone levels is efficacious in improving sexual function, walking, mood, depressive symptoms, anemia, and bone density, all to modest degrees. Testosterone treatment, however, did not improve vitality or cognitive function and was associated with an increase in noncalcified coronary artery plaque volume. Although testosterone treatment was not associated with increased risks of clinical cardiac events or prostate cancer, a much larger and longer trial would be needed to assess these risks with greater certainty.</p><p></p><p class="headingAnchor" id="H1684633792"><span class="h2">Monitoring treatment</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum total </strong><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a><strong> – </strong>If testosterone treatment is prescribed, we recommend monitoring the serum testosterone level during treatment. The author of this topic suggests using a target value in older males that is in the low-normal range for young males (eg, 300 to 400 ng/dL [10.4 to 13.9 nm]) to lower the risk of testosterone-dependent diseases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PSA – </strong>PSA should be repeated three to six months after initiation of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> treatment to determine if it has increased more than 1.4 ng/mL above baseline or to &gt;4 ng/mL. If the increase is reproducible, the patient should be referred for urologic evaluation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematocrit</strong> – Hematocrit should be measured three to six months after initiation of treatment and at least once a year thereafter because <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> stimulates erythropoiesis. A high value can occur because of an excessive dose of testosterone or unmasking of a secondary cause.</p><p></p><p class="headingAnchor" id="H4229620358"><span class="h2">Potential adverse effects</span><span class="headingEndMark"> — </span>There are reasons to think that <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> treatment of older males with low testosterone might exacerbate certain diseases. For example, the prostate gland is testosterone dependent, so it is reasonable to wonder if raising the serum testosterone concentration will increase the risk of prostate cancer or benign prostatic hyperplasia. Erythropoiesis is also testosterone dependent, so raising the testosterone level, especially to supraphysiologic levels, can cause erythrocytosis. Some epidemiologic studies have shown a larger number of cardiovascular events in males treated with testosterone, but others have not. (See  <a class="medical medical_review" href="/z/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism", section on 'Venous thromboembolism'</a> and  <a class="medical medical_review" href="/z/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism", section on 'Cardiovascular risks'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prostate cancer </strong>–<strong> </strong>Prostate cancer is partly <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> dependent [<a href="#rid31">31</a>]. This dependency is illustrated by the current practice of treating males who have metastatic and locally advanced prostate cancer by lowering their serum testosterone concentrations with drugs that decrease testosterone synthesis and/or its action [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/6951.html" rel="external">"Initial systemic therapy for advanced, recurrent, and metastatic noncastrate (castration-sensitive) prostate cancer"</a>.)</p><p></p><p class="bulletIndent1">In the few clinical trials of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> in older males, few cases of prostate cancer occurred [<a href="#rid15">15,17,18,23</a>], but these trials, involving at most 788 males, had too little statistical power to state that testosterone treatment does not increase the risk of prostate cancer. It has been estimated that a trial would require 6000 males randomized to receive testosterone or placebo for five years each to determine if testosterone increases the incidence of prostate cancer by 30 percent [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1">In a 2010 meta-analysis of 51 randomized trials of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy in males designed to look at the primary endpoints of mortality, cardiovascular events and risk factors, prostate outcomes, and erythrocytosis, testosterone treatment was not associated with increased incidence of prostate cancer, need for prostate biopsy, or other prostate outcomes when compared with the placebo/nonintervention group [<a href="#rid33">33</a>]. Results were the same when analyzed by subject age (less than or greater than age 65 years). However, as the study authors emphasize, the number of subjects studied and the quality of the observations were not adequate to say that testosterone does not result in worse prostate outcomes. (See  <a class="medical medical_review" href="/z/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benign prostatic hyperplasia </strong>–<strong> </strong>The <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> dependency of benign prostatic hyperplasia has been known for over 100 years and is the basis for one current medical treatment: use of the 5-alpha-reductase inhibitors, <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> and <a class="drug drug_general" data-topicid="8672" href="/z/d/drug information/8672.html" rel="external">dutasteride</a>, to block the conversion of testosterone to dihydrotestosterone, its active metabolite within the prostate [<a href="#rid34">34</a>]. In the meta-analysis noted above, testosterone therapy had no adverse effect on lower urinary tract symptoms or other prostate outcomes [<a href="#rid33">33</a>]. In the TTrials of 788 males treated for one year, the number of males whose International Prostate Symptom Score increased above 19 (moderately severe) was similar in the testosterone and placebo groups (testosterone 27, placebo 26) [<a href="#rid23">23</a>]. The number of males observed and duration of the observations are not sufficient to say that testosterone does not worsen lower urinary tract symptoms. (See  <a class="medical medical_review" href="/z/d/html/6891.html" rel="external">"Medical treatment of benign prostatic hyperplasia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sleep apnea </strong>–<strong> </strong>Data from a small number of males with hypogonadism suggest that even physiologic replacement of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> increases sleep apnea [<a href="#rid35">35-37</a>], a condition to which older males are already prone. In contrast, in one meta-analysis [<a href="#rid38">38</a>], the frequency of sleep apnea did not differ between testosterone- and placebo-treated males.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythrocytosis </strong>–<strong> </strong><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> treatment of older males, especially with long-acting testosterone esters in doses that have been commonly employed, causes erythrocytosis. In one retrospective trial of 45 males whose average age was 71.8 years and who had relatively low serum bioavailable testosterone concentrations, treatment with 200 mg of testosterone ester (enanthate or cypionate) caused an increase in hematocrit to &gt;52 percent in 11 of them (24 percent) [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1">In the trial described above in which males were randomized to receive <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> enanthate 200 mg/two weeks alone or with <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a>, 14 of 46 males developed an elevated hemoglobin [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1">Even in the TTrials, in which <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> and hemoglobin levels were monitored at least every three months, the dose of testosterone adjusted accordingly, and the incidence of erythrocytosis was relatively low, the seven males who developed erythrocytosis were all in the testosterone group.</p><p></p><p class="bulletIndent1">The potential significance of this adverse effect is that in the Framingham Heart Study, males who were in the highest quintile (46 to 70 percent) with regard to hematocrit had greater overall mortality and cardiovascular mortality than those in the middle two quintiles [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lipids </strong>–<strong> </strong>Both oral and intramuscular administration of high doses of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> have been shown to decrease high-density lipoprotein (HDL) cholesterol concentrations in young hypogonadal males and in males receiving gonadotropin-releasing hormone (GnRH) antagonists, respectively [<a href="#rid41">41,42</a>]. In a meta-analysis of 10 studies of intramuscular testosterone esters and plasma lipids in hypogonadal males, a small, dose-dependent decrease was seen in total cholesterol, low-density lipoprotein (LDL) cholesterol, and HDL [<a href="#rid43">43</a>]. In the TTrials, testosterone was associated in small decreases in both LDL and HDL cholesterol [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular </strong>–<strong> </strong>Data on the risk of cardiovascular complications with <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy have been conflicting, with some epidemiologic studies suggesting no increase in cardiovascular events in older males, while others suggest a possible increase in cardiovascular events in some males who take testosterone. Although this issue remains unclear, the FDA issued a safety announcement on March 3, 2015, stating that it was requiring manufacturers of testosterone products to change its labeling of these products to include a warning of possible increased risk of heart attacks and strokes associated with testosterone use [<a href="#rid13">13</a>]. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism", section on 'Cardiovascular risks'</a>.)</p><p></p><p class="headingAnchor" id="H3315744686"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115296.html" rel="external">"Society guideline links: Testosterone therapy in men"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/115208.html" rel="external">"Society guideline links: Male infertility or hypogonadism"</a>.)</p><p class="headingAnchor" id="H571480616"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/86221.html" rel="external">"Patient education: Androgen replacement in men (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/88640.html" rel="external">"Patient education: Low testosterone in men (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2747677542"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age-related changes serum </strong><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a><strong> </strong>– Serum total testosterone concentrations fall slightly with increasing age, and free testosterone concentrations fall more, although still modestly. (See <a class="local">'Serum total testosterone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Who should be tested? </strong>–<strong> </strong>Older males who have symptoms, physical findings, or other findings suggestive of hypogonadism should be evaluated for low <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a>, just as younger males. (See <a class="local">'Who should be tested?'</a> above.)</p><p></p><p class="bulletIndent1">Initial evaluation should be measurement of the serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> in the early morning, fasting, by liquid chromatography-tandem mass spectroscopy in a laboratory that participates in the Centers for Disease Control and Prevention (CDC)'s <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Flabstandards%2Fhs.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLFIScUk1Y%2FA6K3ujbEhk90ntqdq00Q4z%2BhL0arOPd9DbrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=7457" target="_blank">testosterone Hormone Standardization (HoSt) program</a>. If the result is low for young males (eg, less than 229 ng/dL), the measurement should be performed twice more. (See <a class="local">'Biochemical testing'</a> above.)</p><p></p><p class="bulletIndent1">If the <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> is unequivocally and reproducibly low, we suggest measurement of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to determine if the hypogonadism is primary or secondary. If secondary, we suggest assessment of other pituitary hormones. If the patient has multiple pituitary hormonal deficiencies and/or if the testosterone is less than 200 ng/dL, we suggest MRI of the sella. (See <a class="local">'Biochemical testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidates for </strong><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a><strong> therapy </strong>–<strong> </strong>For older males with unequivocally low serum testosterone levels and symptoms and conditions suggestive of hypogonadism, we suggest testosterone therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). A detailed discussion of the risks and benefits of testosterone therapy is essential in this population. (See <a class="local">'Potential candidates for therapy'</a> above.)</p><p></p><p class="bulletIndent1">We do not prescribe <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> to older males with low testosterone levels in the absence of symptoms and conditions of androgen deficiency (or symptoms without unequivocally low testosterone levels). (See <a class="local">'Potential candidates for therapy'</a> above.)</p><p></p><p class="bulletIndent1">If a digital rectal examination shows a prostate nodule or the prostate-specific antigen (PSA) is &gt;4 ng/mL or &gt;3 ng/mL in males at increased risk of prostate cancer (eg, African American males or those who have a first-degree relative with diagnosed prostate cancer), the patient should be referred for urologic evaluation before prescribing <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a>. (See <a class="local">'Potential adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring therapy </strong>–<strong> </strong>Monitoring includes measurement of serum total <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a>, hematocrit, and PSA as described above. (See <a class="local">'Monitoring treatment'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wu FC, Tajar A, Pye SR, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 2008; 93:2737.</a></li><li><a class="nounderline abstract_t">Handelsman DJ, Yeap B, Flicker L, et al. Age-specific population centiles for androgen status in men. Eur J Endocrinol 2015; 173:809.</a></li><li><a class="nounderline abstract_t">Travison TG, Vesper HW, Orwoll E, et al. Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe. J Clin Endocrinol Metab 2017; 102:1161.</a></li><li><a class="nounderline abstract_t">Travison TG, Araujo AB, Kupelian V, et al. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 2007; 92:549.</a></li><li><a class="nounderline abstract_t">Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002; 87:589.</a></li><li><a class="nounderline abstract_t">Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86:724.</a></li><li><a class="nounderline abstract_t">Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983; 56:1278.</a></li><li><a class="nounderline abstract_t">Mahmoud AM, Goemaere S, El-Garem Y, et al. Testicular volume in relation to hormonal indices of gonadal function in community-dwelling elderly men. J Clin Endocrinol Metab 2003; 88:179.</a></li><li><a class="nounderline abstract_t">Nieschlag E, Lammers U, Freischem CW, et al. Reproductive functions in young fathers and grandfathers. J Clin Endocrinol Metab 1982; 55:676.</a></li><li><a class="nounderline abstract_t">Hellstrom WJ, Overstreet JW, Sikka SC, et al. Semen and sperm reference ranges for men 45 years of age and older. J Androl 2006; 27:421.</a></li><li><a class="nounderline abstract_t">Tajar A, Huhtaniemi IT, O'Neill TW, et al. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab 2012; 97:1508.</a></li><li><a class="nounderline abstract_t">Bhasin S. Testosterone replacement in aging men: an evidence-based patient-centric perspective. J Clin Invest 2021; 131.</a></li><li><a class="nounderline abstract_t">Nguyen CP, Hirsch MS, Moeny D, et al. Testosterone and "Age-Related Hypogonadism"--FDA Concerns. N Engl J Med 2015; 373:689.</a></li><li><a class="nounderline abstract_t">Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018; 103:1715.</a></li><li><a class="nounderline abstract_t">Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84:1966.</a></li><li><a class="nounderline abstract_t">Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84:2647.</a></li><li><a class="nounderline abstract_t">Kenny AM, Prestwood KM, Gruman CA, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001; 56:M266.</a></li><li><a class="nounderline abstract_t">Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89:503.</a></li><li><a class="nounderline abstract_t">Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005; 90:1502.</a></li><li><a class="nounderline abstract_t">Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006; 355:1647.</a></li><li><a class="nounderline abstract_t">Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 2008; 299:39.</a></li><li class="breakAll">Testosterone and aging: Clinical research directions, Liverman CT, Blazer DG (Eds), National Academies Press, Washington DC 2004.</li><li><a class="nounderline abstract_t">Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med 2016; 374:611.</a></li><li><a class="nounderline abstract_t">Cunningham GR, Stephens-Shields AJ, Rosen RC, et al. Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels. J Clin Endocrinol Metab 2016; 101:3096.</a></li><li><a class="nounderline abstract_t">Resnick SM, Matsumoto AM, Stephens-Shields AJ, et al. Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment. JAMA 2017; 317:717.</a></li><li><a class="nounderline abstract_t">Roy CN, Snyder PJ, Stephens-Shields AJ, et al. Association of Testosterone Levels With Anemia in Older Men: A Controlled Clinical Trial. JAMA Intern Med 2017; 177:480.</a></li><li><a class="nounderline abstract_t">Pencina KM, Travison TG, Artz AS, et al. Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open 2023; 6:e2340030.</a></li><li><a class="nounderline abstract_t">Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial. JAMA Intern Med 2017; 177:471.</a></li><li><a class="nounderline abstract_t">Budoff MJ, Ellenberg SS, Lewis CE, et al. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. JAMA 2017; 317:708.</a></li><li><a class="nounderline abstract_t">Cunningham GR, Ellenberg SS, Bhasin S, et al. Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial. J Clin Endocrinol Metab 2019; 104:6238.</a></li><li><a class="nounderline abstract_t">Huggins, C, Hodges, CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1:293.</a></li><li><a class="nounderline abstract_t">Iversen P, Christensen MG, Friis E, et al. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer 1990; 66:1058.</a></li><li><a class="nounderline abstract_t">Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95:2560.</a></li><li><a class="nounderline abstract_t">Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327:1185.</a></li><li><a class="nounderline abstract_t">Matsumoto AM, Sandblom RE, Schoene RB, et al. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol (Oxf) 1985; 22:713.</a></li><li><a class="nounderline abstract_t">Schneider BK, Pickett CK, Zwillich CW, et al. Influence of testosterone on breathing during sleep. J Appl Physiol (1985) 1986; 61:618.</a></li><li><a class="nounderline abstract_t">Liu PY, Yee B, Wishart SM, et al. The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab 2003; 88:3605.</a></li><li><a class="nounderline abstract_t">Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005; 60:1451.</a></li><li><a class="nounderline abstract_t">Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997; 82:3793.</a></li><li><a class="nounderline abstract_t">Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and the risk of cardiovascular disease--the Framingham study: a 34-year follow-up. Am Heart J 1994; 127:674.</a></li><li><a class="nounderline abstract_t">Asscheman H, Gooren LJ, Megens JA, et al. Serum testosterone level is the major determinant of the male-female differences in serum levels of high-density lipoprotein (HDL) cholesterol and HDL2 cholesterol. Metabolism 1994; 43:935.</a></li><li><a class="nounderline abstract_t">Bagatell CJ, Knopp RH, Vale WW, et al. Physiologic testosterone levels in normal men suppress high-density lipoprotein cholesterol levels. Ann Intern Med 1992; 116:967.</a></li><li><a class="nounderline abstract_t">Whitsel EA, Boyko EJ, Matsumoto AM, et al. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 2001; 111:261.</a></li><li><a class="nounderline abstract_t">Mohler ER 3rd, Ellenberg SS, Lewis CE, et al. The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials. J Clin Endocrinol Metab 2018; 103:681.</a></li></ol></div><div id="topicVersionRevision">Topic 7457 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18270261" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26385186" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Age-specific population centiles for androgen status in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28324103" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17148559" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11836290" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11158037" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6841562" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Loss of circadian rhythmicity in blood testosterone levels with aging in normal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12519849" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Testicular volume in relation to hormonal indices of gonadal function in community-dwelling elderly men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6809780" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Reproductive functions in young fathers and grandfathers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16452528" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Semen and sperm reference ranges for men 45 years of age and older.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22419720" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33586676" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Testosterone replacement in aging men: an evidence-based patient-centric perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26287846" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Testosterone and "Age-Related Hypogonadism"--FDA Concerns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29562364" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10372695" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effect of testosterone treatment on bone mineral density in men over 65 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10443654" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11320105" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14764753" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15572415" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17050889" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : DHEA in elderly women and DHEA or testosterone in elderly men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18167405" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18167405" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26886521" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effects of Testosterone Treatment in Older Men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27355400" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28241356" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28241237" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Association of Testosterone Levels With Anemia in Older Men: A Controlled Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37889486" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28241231" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28241355" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504596" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2144207" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20525906" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1383816" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4017261" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3745052" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Influence of testosterone on breathing during sleep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12915643" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The short-term effects of high-dose testosterone on sleep, breathing, and function in older men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16339333" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9360543" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8122618" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hematocrit and the risk of cardiovascular disease--the Framingham study: a 34-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8052149" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Serum testosterone level is the major determinant of the male-female differences in serum levels of high-density lipoprotein (HDL) cholesterol and HDL2 cholesterol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1586105" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Physiologic testosterone levels in normal men suppress high-density lipoprotein cholesterol levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11566455" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29253154" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
